2. NF-κB Immunology/Inflammation Apoptosis
  3. TNF Receptor Interleukin Related NF-κB NO Synthase
  4. Malvidin-3-glucoside chloride

Malvidin-3-glucoside chloride  (Synonyms: Malvidin-3-O-glucoside chloride; Oenin chloride)

Cat. No.: HY-125740 Purity: 99.87%
SDS
COA
Handling Instructions Technical Support

Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health.

For research use only. We do not sell to patients.

Malvidin-3-glucoside chloride Chemical Structure

Malvidin-3-glucoside chloride Chemical Structure

CAS No. : 7228-78-6

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Malvidin-3-glucoside chloride:

Malvidin-3-glucoside chloride Related Antibodies

Top Publications Citing Use of Products

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health[1][2][3].

IC50 & Target

IL-6

 

eNOS

 

In Vitro

Malvidin-3-glucoside (1, 10, 50, 100 μM; pretreatment for 18 h + TNF-α stimulation for 6 h) inhibits TNF-α-induced MCP-1, ICAM-1, VCAM-1 protein and mRNA expressions in human umbilical vein endothelial cells (HUVECs) in a concentration-dependent manner, reduces IκB-α degradation and inhibits NF-κB p65 subunit nuclear translocation[1].
Malvidin-3-glucoside (25 μM; pretreatment 14 h+ ONOO- aggression) upregulates eNOS mRNA and activity in bovine aortic endothelial cells (BAECs), increases NO production, while inhibiting peroxynitrite-induced iNOS, COX-2 expression and IL-6 production, and blocking NF-κB activation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Malvidin-3-glucoside chloride Related Antibodies

Cell Viability Assay[1]

Cell Line: Human umbilical vein endothelial cells (HUVECs)
Concentration: 1 μM, 10 μM, 50 μM, 100 μM
Incubation Time: 18 h pretreatment with malvidin-3-glucoside, followed by 6 h stimulation with TNF-α
Result: Significantly reduced the protein levels of MCP-1, ICAM-1, and VCAM-1 in cell supernatants in a concentration-dependent manner.
Resulted 35.9% MCP-1, 54.4% ICAM-1, and 44.7% VCAM-1 protein increases inhibition at 1 μM; and suppressed over 90% mRNA expressions of MCP-1 and ICAM-1 as well, with 100 μM.

Western Blot Analysis[1]

Cell Line: Human umbilical vein endothelial cells (HUVECs)
Concentration: 1 μM, 10 μM, 50 μM, 100 μM
Incubation Time: 18 h pretreatment with malvidin-3-glucoside, followed by 6 h stimulation with TNF-α
Result: Decreased IκB-α degradation (inhibition rates: 84.8% at 50 μM).

Immunofluorescence[1]

Cell Line: Human umbilical vein endothelial cells (HUVECs)
Concentration: 1 μM, 10 μM, 50 μM, 100 μM
Incubation Time: 18 h pretreatment with malvidin-3-glucoside, followed by 6 h stimulation with TNF-α
Result: Reduced nuclear translocation of p65 in immunofluorescence (IF) assay.
In Vivo

Malvidin-3-glucoside (24 mg/kg diet; dietary supplementation; daily ad libitum; 50 days) improves colon tissue pathological damage in the DSS (HY-116282)-induced colitis model in mice, upregulates the expression of the anti-inflammatory cytokine IL-10, regulates the intestinal microbial composition (restoring the Firmicutes/Bacteroidetes ratio and reducing the abundance of pathogenic Ruminococci), and reshapes the intestinal metabolome (reducing the levels of pro-inflammatory metabolites such as ceramide)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6J mice (4-5 weeks old), Dextran sulfate sodium (HY-116282C)-induced colitis model[3]
Dosage: 24 mg/kg Malvidin-3-glucoside in diet
Administration: Dietary supplementation ad libitum, daily for 50 days (including 8 days pre-Dextran sulfate sodium (DSS) induction and two DSS cycles)
Result: Significantly reduced histopathological scores by improving crypt dilation, ulceration, and smooth muscle thickness in colonic tissues.
Increased IL-10 mRNA expression in colon mucosa.
Decreased microbial evenness but enhanced microbial interactions, with Firmicutes/Bacteroidetes ratio restored from 0.38 (DSS group) to 0.56.
Molecular Weight

528.89

Formula

C23H25ClO12
CAS No.
Appearance

Solid

Color

Brown to black

SMILES

OC1=CC2=C(C=C(C(C3=CC(OC)=C(C(OC)=C3)O)=[O+]2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(O)=C1.[Cl-]
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (47.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8908 mL 9.4538 mL 18.9075 mL
5 mM 0.3782 mL 1.8908 mL 3.7815 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (2.36 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.25 mg/mL (2.36 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.87%

SDS (393 KB)

COA (260 KB) RP-HPLC (246 KB) MS (68 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8908 mL 9.4538 mL 18.9075 mL 47.2688 mL
5 mM 0.3782 mL 1.8908 mL 3.7815 mL 9.4538 mL
10 mM 0.1891 mL 0.9454 mL 1.8908 mL 4.7269 mL
15 mM 0.1261 mL 0.6303 mL 1.2605 mL 3.1513 mL
20 mM 0.0945 mL 0.4727 mL 0.9454 mL 2.3634 mL
25 mM 0.0756 mL 0.3782 mL 0.7563 mL 1.8908 mL
30 mM 0.0630 mL 0.3151 mL 0.6303 mL 1.5756 mL
40 mM 0.0473 mL 0.2363 mL 0.4727 mL 1.1817 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Malvidin-3-glucoside chloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Malvidin-3-glucoside7228-78-6Malvidin-3-O-glucosideOeninTNF ReceptorInterleukin RelatedNF-κBNO SynthaseTumor Necrosis Factor ReceptorTNFRILNuclear factor-κBNuclear factor-kappaBNitric oxide synthasesNOSwineanthocyanindepressionstressinflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Malvidin-3-glucoside chloride
Cat. No.:
HY-125740
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.